Prophylactic measures such as vancomycin, povidone-iodine and saline irrigation yielded similar rates of periprosthetic joint infection and wound complications at 3 months for high-risk patients ...

Clostridioides difficile infection is a major healthcare-associated infection, causing significant morbidity and mortality, ...

Increased antibiotic use can lead, seemingly paradoxically, to more problematic infections, as the bacteria evolve to resist ...

Q4 2024 Earnings Call Transcript March 18, 2025 Operator: Greetings and welcome to the Acurx Pharmaceuticals Fourth Quarter ...

Purpose. The feasibility of using a limitedsampling algorithm for administration of vancomycin for treatment of vascular-access-related bacteremia in outpatient high flux hemodialysis was ...

Increased antibiotic use can lead, seemingly paradoxically, to more problematic infections, as the bacteria evolve to resist ...

A company presentation will take place during the conference’s Innovation track on Friday, March 28th at 9:00am. NeauxCancer conference’s Innovation track spotlights the most promising emerging ...

Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, ...

Waite, Pharm.D; Donald P. Alexander, Pharm.D; C. Andrew DeRyke, Pharm.D Despite the higher frequency of target vancomycin troughs among patients dosed according to the revised protocol ...